Eton Pharmaceuticals Inc (ETON)vsJohnson & Johnson (JNJ)
ETON
Eton Pharmaceuticals Inc
$24.12
+2.29%
HEALTHCARE · Cap: $628.09M
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 120428% more annual revenue ($96.36B vs $79.95M). JNJ leads profitability with a 21.8% profit margin vs -5.8%. JNJ earns a higher WallStSmart Score of 59/100 (C).
ETON
Hold35
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ETON.
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 82.7% year-over-year
Strong operational efficiency at 21.0%
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Trading at 24.9x book value
ROE of -18.2% — below average capital efficiency
Earnings declined 12.6%
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ETON
The strongest argument for ETON centers on Revenue Growth, Operating Margin. Revenue growth of 82.7% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : ETON
The primary concerns for ETON are Market Cap, Price/Book, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ETON profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
ETON carries more volatility with a beta of 0.97 — expect wider price swings.
ETON is growing revenue faster at 82.7% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 35/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eton Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?